News and Breakthroughs

Men with advanced prostate cancer who were treated based on the genetic makeup of their cancer survived significantly longer than those treated with standard treatments, according to a new study.

Inhibiting an epigenetic regulator called DOT1L could be a key to slowing treatment-resistant prostate cancer, according to a recent Northwestern Medicine study.

On June 7, not even a worldwide pandemic could prevent hope, love, and support from flourishing in the fight against cancer. Celebrating together while safely apart, the 27th Annual Cancer Survivors’ Celebration Walk & 5K, hosted by the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, pivoted quickly to become a virtual event to applaud cancer survivors and all those who support them.

Daniela Matei, MD, Diana, Princess of Wales Professor of Cancer Research at Northwestern Feinberg School of Medicine, Chicago, grew up Sibiu, a picturesque Romanian city situated at the foothills of the Cindrel Mountains in historic Transylvania. “Both of my parents were physicians, and some of my early passion for science was ignited by their professions. But as a child, I didn’t want to pursue a career as a doctor; my dream was to become a writer.”

Genomic alterations in prostate cancer therapeutic targets were found to be similar between African American and European American men, suggesting that existing precision medicine approaches could equally benefit both groups if applied equitably, according to a recent study.

A machine-learning program called Peakachu can reveal previously unknown chromatin loops, according to a Northwestern Medicine study published in Nature Communications.

Measuring epigenetic signatures in blood plasma could help classify brain tumors, according to a study published in Nature Medicine.

My cancer journey began when I was diagnosed with a stage 3/4 (Synovial/soft tissue) sarcoma in 2013 at age 23.

A specific cell signaling protein may be used to enhance the sensitivity of medulloblastoma tumors to immunotherapy, potentially improving quality of life for patients with the malignant pediatric brain cancer.

An emerging cancer treatment also helps prevent cells from turning into viral factories by interfering with HIV infection processes inside the cell, according to a recent study.